BR112019004299A2 - peptídeos de nnif e relacionados a nnif e métodos relacionados - Google Patents

peptídeos de nnif e relacionados a nnif e métodos relacionados

Info

Publication number
BR112019004299A2
BR112019004299A2 BR112019004299A BR112019004299A BR112019004299A2 BR 112019004299 A2 BR112019004299 A2 BR 112019004299A2 BR 112019004299 A BR112019004299 A BR 112019004299A BR 112019004299 A BR112019004299 A BR 112019004299A BR 112019004299 A2 BR112019004299 A2 BR 112019004299A2
Authority
BR
Brazil
Prior art keywords
nnif
methods
peptides
cancer
patients
Prior art date
Application number
BR112019004299A
Other languages
English (en)
Portuguese (pt)
Inventor
S Weyrich Andrew
Con Yost Christian
A Zimmerman Guy
Schiffman Joshua
Original Assignee
The Univ Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Utah Research Foundation filed Critical The Univ Of Utah Research Foundation
Publication of BR112019004299A2 publication Critical patent/BR112019004299A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112019004299A 2016-09-02 2017-09-05 peptídeos de nnif e relacionados a nnif e métodos relacionados BR112019004299A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US201762492019P 2017-04-28 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (1)

Publication Number Publication Date
BR112019004299A2 true BR112019004299A2 (pt) 2019-05-28

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004299A BR112019004299A2 (pt) 2016-09-02 2017-09-05 peptídeos de nnif e relacionados a nnif e métodos relacionados

Country Status (13)

Country Link
US (1) US10857201B2 (https=)
EP (1) EP3506924A4 (https=)
JP (1) JP2019534247A (https=)
KR (1) KR20190045271A (https=)
CN (1) CN109937047A (https=)
AU (1) AU2017321965A1 (https=)
BR (1) BR112019004299A2 (https=)
CA (1) CA3035770A1 (https=)
MX (1) MX2019002479A (https=)
RU (1) RU2019109049A (https=)
SG (1) SG11201901830UA (https=)
WO (1) WO2018045371A2 (https=)
ZA (1) ZA201901942B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158108A1 (en) * 2020-05-04 2023-05-25 University Of Utah Research Foundation Immunothrombosis in covid-19 acute respiratory distress syndrome
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP4219534A3 (en) * 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Also Published As

Publication number Publication date
JP2019534247A (ja) 2019-11-28
EP3506924A2 (en) 2019-07-10
CA3035770A1 (en) 2018-03-08
RU2019109049A3 (https=) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (en) 2020-05-20
ZA201901942B (en) 2020-10-28
KR20190045271A (ko) 2019-05-02
MX2019002479A (es) 2019-09-19
WO2018045371A2 (en) 2018-03-08
SG11201901830UA (en) 2019-03-28
RU2019109049A (ru) 2020-10-05
US20190201487A1 (en) 2019-07-04
WO2018045371A3 (en) 2018-04-12
CN109937047A (zh) 2019-06-25
AU2017321965A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790660A1 (ru) Ингибитор киназ
GT201200318A (es) Anticuerpos hacia gdf8 humano
IL280145A (en) Methods and compositions using recombinant dendritic cells for cancer therapy
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX387283B (es) Tratamiento del cancer con tg02.
IL284414A (en) Methods and compositions for the treatment of fabry disease
LT3220916T (lt) Vėžio gydymo n-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5- (etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4’-(morfolinometil)-[1,1’- bifenil]-3-karboksamidu būdas
MX2024011262A (es) Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa.
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
MX2016010173A (es) Metodos de tratamiento de enfermedad de alzheimer.
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
UA124939C2 (uk) СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
IL292186A (en) Compositions and methods for treating blood disorders
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2791 DE 02-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.